Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.
Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Advances in understanding and treating ADHD. BMC Med. 2011;9:72.
Stein MA. Impairment associated with adult ADHD. CNS Spectr. 2008;13:9–11.
World Health Organisation. International statistical classification of diseases and related health problems, ICD-10. 4th ed. Geneva: World Health Organisation; 2010.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR). Washington, DC: The Press; 2000.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Arlington: American Psychiatric Publishing; 2013.
Parens E, Johnston J. Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies. Child Adolesc Psychiatry Ment Health. 2009;3:1.
Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83–105.
Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs. 2010;24:843–66.
Coghill D. Pragmatic measures in paediatric psychopharmacology–are we getting it right? Eur Neuropsychopharmacol. 2011;21:571–83.
American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007–22.
Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476–95.
Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie. Hyperkinetische Störungen (F90). In: Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie, editor. Leitlinien zur Diagnostik und Therapie von psychischen Störungen in Säuglings, Kindes- und Judendalter. überarbeitete Auflage ed. Cologne: Deutscher Ärtze Verlag; 2007.
Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S–49S.
National Collaborating Centre for Mental Health (commissioned by the National Institute for Health & Clinical Excellence). Diagnosis and management of ADHD in children, young people and adults. National clinical practice guideline Number 72. London: The British Psychological Society and The Royal College of Psychiatrists; 2009.
Scottish Intercollegiate Guidelines Network (SIGN). Management of attention deficit and hyperactivity disorders in children and young people—a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network (SIGN); 2009.
Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):I7–30.
The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 3rd ed. Toronto: CADDRA; 2011.
Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450–63.
Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:395–405.
Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69:1364–73.
Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.
Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.
Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;. doi:10.1016/j.euroneuro.2012.11.012.
Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G. Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):I63–71.
Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19:709–18.
Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21:581–8.
Riley AW, Robertson JA, Forrest CB, Green BF, Rebok GW, Starfield B. Technical Manual for the Child Health and Illness Profile-Child Edition (CHIP-CE) Parent and Child Report Forms (Version 1.0). Baltimore: Johns Hopkins University; 2001.
Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care. 2004;42:210–20.
The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Weiss Functional Impairment Rating Scale—Parent Report (WFIRS-P); 2000. http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011WFIRS_P.pdf (Accessed 18 Mar 2013).
The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Weiss Functional Impairment Rating Scale (WFIRS) instructions; 2000 http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011WFIRSInstructions.pdf (Accessed 18 Mar 2013).
Cohen J. A power primer. Psychol Bull. 1992;112:155–9.
Schacht A, Escobar R, Wagner T, Wehmeier PM. Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials. Atten Defic Hyperact Disord. 2011;3:335–49.
Dell’Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol. 2009;19:822–34.
Escobar R, Montoya A, Polavieja P, Cardo E, Artigas J, Hervas A, et al. Evaluation of patients’ and parents’ quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:253–63.
Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007;23:379–94.
Svanborg P, Thernlund G, Gustafsson PA, Hagglof B, Schacht A, Kadesjo B. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18:725–35.
Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(990–1002):e2.
San Juan AF, Chamorro-Vina C, Mate-Munoz JL, Fernandez del Valle M, Cardona C, Hernandez M, et al. Functional capacity of children with leukemia. Int J Sports Med. 2008;29:163–7.
Gerson AC, Riley A, Fivush BA, Pham N, Fiorenza J, Robertson J, et al. Assessing health status and health care utilization in adolescents with chronic kidney disease. J Am Soc Nephrol. 2005;16:1427–32.
Dodson JL, Diener-West M, Gerson AC, Kaskel FJ, Furth SL. An assessment of health related quality of life using the child health and illness profile-adolescent edition in adolescents with chronic kidney disease due to underlying urological disorders. J Urol. 2007;178:660–5.
Dodson JL, Furth SL, Hsiao CJ, Diener-West M, Levey EB, Wu AW, et al. Health related quality of life in adolescents with abnormal bladder function: an assessment using the Child Health and Illness Profile-Adolescent Edition. J Urol. 2008;180:1846–51.
Riano-Galan I, Malaga S, Rajmil L, Ariceta G, Navarro M, Loris C, et al. Quality of life of adolescents with end-stage renal disease and kidney transplant. Pediatr Nephrol. 2009;24:1561–8.
Okelo SO, Wu AW, Krishnan JA, Rand CS, Skinner EA, Diette GB. Emotional quality-of-life and outcomes in adolescents with asthma. J Pediatr. 2004;145:523–9.
Forrest CB, Starfield B, Riley AW, Kang M. The impact of asthma on the health status of adolescents. Pediatrics. 1997;99:E1.
Wehmeier PM, Schacht A, Escobar R, Savill N, Harpin V. Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and attention deficit/hyperactivity disorder core symptoms: meta-analysis of five atomoxetine trials. Child Adolesc Psychiatry Ment Health. 2010;4:30.
Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754–63.
Coghill D, Danckaerts M, Sonuga-Barke E, Sergeant J. Practitioner review: quality of life in child mental health—conceptual challenges and practical choices. J Child Psychol Psychiatry. 2009;50:544–61.
Estrada MD, Rajmil L, Herdman M, Serra-Sutton V, Tebe C, Alonso J, et al. Reliability and validity of the Spanish version of the Child Health and Illness Profile Child-Edition/Child Report Form (CHIP-CE/CRF). Qual Life Res. 2012;21:909–14.
Estrada MD, Rajmil L, Serra-Sutton V, Tebe C, Alonso J, Herdman M, et al. Reliability and validity of the Spanish version of the Child Health and Illness Profile (CHIP) Child-Edition, Parent Report Form (CHIP-CE/PRF). Health Qual Life Outcomes. 2010;8:78.